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662Objective: Todeterminewhethermediastinal lymph nodedissection improves survival comparedwithmediastinal
lymph node sampling in patients undergoing resection for N0 or nonhilar N1, T1, or T2 non–small cell lung cancer.
Methods: Patients with non–small cell lung cancer underwent sampling of 2R, 4R, 7, and 10R for right-sided
tumors and 5, 6, 7, and 10L for left-sided tumors. If all tumors were negative for malignancy, patients were ran-
domized to no further lymph node sampling (mediastinal lymph node sampling) or complete mediastinal lymph
node dissection.
Results: Of 1111 patients randomized, 1023 (mediastinal lymph node sampling in 498, mediastinal lymph node
dissection in 525) were eligible and evaluable. Therewere no significant differences between the 2 groups in terms
of demographics, Eastern Cooperative Oncology Group status, histology, cancer location, type or extent of resec-
tion, and pathologic stage. Occult N2 disease was found in 21 patients in the mediastinal lymph node dissection
group. At a median follow-up of 6.5 years, 435 patients (43%) have died: mediastinal lymph node sampling in 217
(44%) and mediastinal lymph node dissection in 218 (42%). The median survival is 8.1 years for mediastinal
lymph node sampling and 8.5 years for mediastinal lymph node dissection (P¼ .25). The 5-year disease-free sur-
vival was 69% (95% confidence interval, 64–74) in the mediastinal lymph node sampling group and 68% (95%
confidence interval, 64–73) years in the mediastinal lymph node dissection group (P ¼ .92). There was no differ-
ence in local (P ¼ .52), regional (P ¼ .10), or distant (P ¼ .76) recurrence between the 2 groups.
Conclusions: If systematic and thorough presection sampling of the mediastinal and hilar lymph nodes is neg-
ative, mediastinal lymph node dissection does not improve survival in patients with early stage non–small cell
lung cancer, but these results are not generalizable to patients staged radiographically or those with higher stage
tumors. (J Thorac Cardiovasc Surg 2011;141:662-70)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Cardiovascular SurgLung cancer is the leading cause of cancer deaths.1 Non–
small cell lung cancer (NSCLC) may be curable by surgical
resection; however, even tumors that appear localized by
imaging may have lymph node metastases. Lymph node
assessment is important for accurate staging of NSCLC.
However, the extent of lymph node removal required and
the impact of mediastinal node removal on survival are con-
troversial. Unfortunately, in a pattern of care study, only
57.3% of patients had any mediastinal nodes removed at
the time of pulmonary resection.2
Studies addressing the survival benefit of mediastinal
lymph node dissection (MLND) have been inconclusive,
with only 1 of 3 previous randomized trials reporting a sur-
vival advantage.3 Proponents argue thatMLND, by removing
occult N2 disease, would decrease recurrence and increase
survival. However, distance metastases as the first site of re-
currence develop in two thirds of patients with N2 disease.4
TheAmericanCollege of SurgeryOncologyGroup (ACO-
SOG) Z0030 study was a randomized, multi-institutional,ery c March 2011
Abbreviations and Acronyms
ACOSOG ¼ American College of Surgery
Oncology Group
CI ¼ confidence interval
CT ¼ computed tomography
MLND ¼ mediastinal lymph node dissection
MLNS ¼ mediastinal lymph node sampling
NSCLC ¼ non–small cell lung cancer
VATS ¼ video-assisted thoracic surgery
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sampling (MLNS) during pulmonary resection for patients
with early-stage NSCLC. This study addresses the question
of whether survival is improved by MLND compared with
MLNS in early-stage NSCLC and compares recurrence
patterns.MATERIALS AND METHODS
The protocol was approved by a central institutional review board and
the institutional review board at each participating institution. All patients
provided written informed consent before trial enrollment.
Participating surgeons were required to read a detailed description of the
technique of MLND and watch an instructional video. All operative notes
and pathology reports were reviewed by the principal investigators (M.S.A.
or G.E.D.) for completeness of the mediastinal dissection. Specifically, it
was ascertained that additional lymph nodes were removed during
MLND per protocol. Lymph nodes were named according to the American
Thoracic Society lymph node stations.5 Eligibility requirements and
methods have been published.6 Patients with proven NSCLC underwent
a rigorous mediastinal and hilar lymph node sampling per protocol before
randomization. For tumors in the right lung, lymph node stations 2R, 4R, 7,
and 10R were sampled. For tumors in the left lung, stations 5, 6, 7, and 10L
were sampled. Any suspicious lymph nodes were also biopsied. The sur-
geon had the option of sampling by mediastinoscopy (2R/L, 4R/L, and
7), thoracotomy, or video-assisted thoracic surgery (VATS). Station 10 no-
des were sampled at thoracotomy or VATS. If all sampled lymph nodes
showed no evidence of cancer on frozen-section examination, patients
were randomized intraoperatively via telephone by the central coordinating
center to lymph node sampling only (MLNS) with no further lymph node
removal or to complete MLND.
MLND was performed according to a previously described protocol.7
For tumors on the right side, all lymph tissue was removed from an area
bounded by the takeoff of the right upper lobe bronchus, innominate artery,
superior vena cava, and trachea (stations 2R and 4R). Lymph nodes in the
prevascular area, adjacent to the superior vena cava, and retrotracheal nodes
were removed. Complete MLND for tumors on the left involved removing
all lymph tissue between the phrenic and vagus nerves extending down to
the left main stem bronchus (stations 5 and 6). At the completion of the
dissection, the aortopulmonary windowwas free of lymph tissue and the re-
current nerve was preserved. Regardless of the side of the tumor, complete
subcarinal lymph node dissection was performed, removing all lymph tis-
sue caudal to the carina and both left and right mainstem bronchi (station 7).
Lymph nodes in the inferior pulmonary ligament and adjacent to the caudal
half of the esophagus were also removed (stations 8 and 9). When the
dissection was complete, the mainstem bronchi, posterior pericardium,
and esophagus were free of all lymph tissue. In both arms, all lobar and in-
terlobar lymph nodes were resected during the lung resection.The Journal of Thoracic and CaStatistical Methods
The target accrual for this study was 1037, with the final analysis to oc-
cur after 459 deaths. This was determined on the basis of the assumption
that after surgery there would be 4 pathologic stage groups—pT1N0,
pT2N0, pN1, and pN2/pIIIA, with expected proportions of 40%, 30%,
15%, and 15%, respectively. For calculating the sample size, it was
assumed that the 5-year survival in the sampling arm for the 4 groups
would be 75%, 60%, 40%, and 30%, respectively. However, observed
proportions of the 4 pathologic stage groups in the sampling arm of the
study—pT1N0, pT2N0, pN1, and pN2/pIIIA— were 41%, 41%, 13%,
and 4%, respectively. In addition, the observed 5-year survival in the sam-
pling arm for the 4 groups was 74%, 59%, 44%, and 27%, respectively.
This translated to a weighted yearly death hazard rate of 0.0998 (assuming
survival time is exponentially distributed). An 8% higher 5-year survival in
arm 2 was considered clinically important. Under exponential distribution
assumptions, this translated to a death hazard rate that is 25% less, or a haz-
ard ratio of 0.75 (0.0751/0.0998). In calculating the sample size for
survival, the following specifications were made: 1-sided significance level
of .05, statistical power of 0.90, uniform patient accrual, a 5-year accrual
period, and a follow-up period of 5 years.
Patient and surgical characteristics were compared between treatment
arms using the chi-square test for categoric variables, Kruskal–Wallis
test for continuous variables, and Wilcoxon test for ordinal variables. Cu-
mulative time to event (survival, recurrence) probabilities was estimated
using the Kaplan–Meier method. The log-rank test was used to compare
survival and recurrence by treatment group. For the recurrence analysis,
deaths were censored. An additional comparison of local, regional, and dis-
tant recurrencewas performed using a cumulative incidence approach. This
methodology was used to account for competing risks when determining
recurrence rates because only first sites of recurrence were recorded. Death
was considered a competing event. One-sided statistical tests were used for
the primary end point of overall survival.
RESULTS
From June 1999 to February 2004, 1111 patients were
randomized by 102 different surgeons from 63 institutions.
All participating surgeons were general thoracic surgeons
and diplomats of the American Board of Thoracic Surgery
or equivalent. After randomization, retrospective review
found 155 patients (13.9%) to be ineligible (Figure 1). In
67 of these patients, the reason for ineligibility was minor
(eg, timing violation), and these patients were included in
this analysis. The remaining 88 patients (57 in the MLNS
group and 31 in the MLND group) were excluded for ma-
jor violations, including incorrect clinical stage in 29 pa-
tients, inadequate lymph node sampling in 14 patients,
benign disease in 6 patients, insufficient documentation
in 5 patients, and other reasons in 34 patients. All analyses
were performed on the 1023 (MLNS in 498 and MLND in
525) eligible subjects, and additional intent-to-treat analy-
ses were performed on all randomized subjects. Details of
the demographic profile have been published (Table 1).6
The median age was 68 years (range, 23–89 years), with
a slight male predominance (n ¼ 529; 52%); 955 (93%)
were white, 46 (5%) were black, and 22 (2%) were of
other racial backgrounds. Most patients had an Eastern
Cooperative Oncology Group performance score of zero
(n ¼ 688; 67%) or 1 (n ¼ 307; 30%). There were no clin-
ically significant differences in demographic profile orrdiovascular Surgery c Volume 141, Number 3 663
TABLE 1. Patient and surgical characteristics of the patients in each
arm of the American College of Surgery Oncology Group Z0030 Study
Lymph node
sampling arm
(n ¼ 498)
Lymph node
dissection arm
(n ¼ 525) P*
Male 257 (52%) 272 (52%) .95
Median age, y (range) 68 (23–89) 67 (37–87) .026
ECOG performance score
0 344 (69%) 344 (66%) .34
1 139 (28%) 168 (32%)
2 15 (3%) 13 (3%)
Tumor locationy
RUL 193 (39%) 194 (37%) .55
RML 36 (7%) 29 (6%) .26
RLL 88 (18%) 101 (19%) .52
LUL 129 (26%) 144 (27%) .58
LLL 58 (12%) 64 (12%) .79
Histology .53
Squamous cell 132 (27%) 141 (27%)
Adenocarcinoma 195 (39%) 228 (44%)
Large cell 27 (5%) 22 (4%)
Bronchoalveolar 36 (7%) 32 (6%)
Other NSCLC 106 (21%) 99 (19%)
Type of resectionz .66
Segmentectomy 36 (7%) 34 (7%)
Lobectomy 379 (76%) 385 (74%)
Bilobectomy 18 (4%) 25 (5%)
Pneumonectomy 18 (4%) 24 (5%)
Combination 45 (9%) 55 (11%)
Extent of resection .36
R0 488 (98%) 512 (98%)
R1 10 (2%) 9 (2%)
R2 0 (0%) 2 (0.4%)
Stage .34
IA 211 (43%) 212 (41%)
IB 205 (41%) 213 (41%)
IIA 13 (3%) 24 (5%)
IIB 56 (11%) 41 (8%)
IIIA 4 (1%) 22 (4%)
IIIB 8 (2%) 11 (2%)
ECOG, Eastern Cooperative Oncology Group; NSCLC, non–small cell lung cancer;
RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper
lobe; LLL, left lower lobe. *Chi-square test, Kruskal–Wallis test, or Wilcoxon test as
appropriate. yCounts do not sum to 100% because some patients had disease that in-
volved multiple lobes. zThe type of resection could not be determined in 4 patients.
* Note: intent to treat analyses were also performed. 
Randomized n=1111 
Allocated to MLNS 
(n =555) 
235 deaths
57 excluded from 
primary analysis 
Allocated to MLND 
(n =556) 
231 deaths 
31 excluded from 
primary analysis 
MLNS
Analyzed* (n =498) 
217 deaths 
MLND
Analyzed* (n =525) 
218 deaths 
FIGURE 1. Consort diagram. MLNS,Mediastinal lymph node sampling;
MLND, mediastinal lymph node dissection.
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study arms.
Approximately 61% of tumors were located in the upper
lobes, and adenocarcinoma was the predominant histology
(42%) (Table 1). Mediastinoscopy was performed in 303
patients overall; MLNS in 162 patients (33%) and MLND
in 141 patients (27%) (P ¼ .05). Per protocol, anatomic
pulmonary resections were performed in all patients: lobec-
tomy in 764 patients (75%), segmentectomy in 70 patients
(7%), pneumonectomy in 42 patients (4%), and bilobec-
tomy in 43 patients (4%). Combinations were performed
in 100 patients (10%). Resection was complete (R0) in
1000 patients (98%), incomplete (R1) in 19 patients
(2%), and grossly incomplete (R2) in 2 patients (0.2%).
There was no statistical difference in type of resection, op-
erative approach (thoracotomy vs VATS), or completeness
of resection between the MLND and MLNS groups6
(Table 1).
Only 67 patients (7%) underwent resection via VATS.
There was no difference in the number of lymph nodes re-
moved by VATS compared with open resections (median
nodes removed: 15 vs 19, P ¼ .17). However, more nodes
were harvested via lobectomy (median ¼ 18) compared
with segmentectomy (median ¼ 14) (P ¼ .006).
After prerandomization sampling, a median of 18 addi-
tional nodes were removed in those patients randomized to
MLND (range, 1–72 for right-sided tumors; 4–69 for left-
sided tumors), and 516 patients (99%) had at least 6 nodes
removed from 3 mediastinal node stations.7 With MLND, at
least 1 additional mediastinal lymph node was removed
from each station, with a median of 1 to 4 nodes removed.664 The Journal of Thoracic and Cardiovascular SurgThe pathologic stages are shown in Table 1. Forty-five
patients (4.4%) had pathologic stage IIIA or IIIB: 12 in
the MLNS arm and 33 in the MLND arm. Positive medias-
tinal lymph nodes (N2) were discovered in 21 patients who
had negative sampling and were randomized to MLND
(4%; 95% confidence interval [CI], 2.5–6.1).There were
303 patients who underwent mediastinoscopy for lymph
node sampling before randomization. Despite a negative
mediastinoscopy, after MLND, 8 patients (2.6%) were
found to be N2 on final pathology, whereas of the 718
patients who had lymph node sampling at thoracotomy orery c March 2011
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FIGURE 2. Overall survival. MLNS, Mediastinal lymph node sampling; MLND, mediastinal lymph node dissection.
TABLE 2. Overall and disease-free survival estimates on all eligible
patients
Time
MLNS (N ¼ 498) estimate
(95% CI)
MNLD (n ¼ 525) estimate
(95% CI)
Overall survival
2 y 85.1 (82.0–88.3) 83.0 (79.8–86.4)
4 y 67.8 (63.7–72.2) 70.5 (66.5–74.6)
6 y 58.1 (53.7–62.9) 61.4 (57.1–66.0)
8 y 50.9 (45.9–56.5) 52.4 (47.6–57.7)
Disease-free survival
2 y 79.5 (75.7–83.4) 80.5 (76.9–84.3)
4 y 70.6 (66.2–75.2) 71.7 (67.4–76.2)
6 y 65.2 (60.4–70.4) 66.3 (61.8–71.3)
8 y 61.1 (55.4–67.3) 59.4 (53.8–65.6)
MLNS, Mediastinal lymph node sampling; MLND, mediastinal lymph node dissec-
tion; CI, confidence interval.
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pathology. The reason for designation of stage IIIA/B in
the 12 patients in the MLNS arm and 12 patients (non-
N2) in the MLND arm included another cancer in the
same lobe, tumor less than 2 cm from carina, involvement
of phrenic nerve, and tracheal involvement.
In the group who had initial sampling by mediastino-
scopy, 56 patients (19%) were found to be N1 positive on
final pathology compared with 71 patients (10%) who
had sampling by thoracotomy or VATS. There was no dif-
ference in survival between patients who had their initial
nodal assessment by mediastinoscopy and those assessed
by thoracotomy or VATS.
At a median follow-up of 6.5 years (range, 0–10.1 years),
466 (42%) of the 1111 patients have died: 235 (42%) in the
MLNS arm and 231 (42%) in the MLND arm. Of the 1023
eligible patients, 217 (44%) died in the MLNS arm and 218
(42%) died in the MLND arm. The median survival was 8.1
years (95% CI, 7.0–9.0) in the MLNS group and 8.5 years
(95% CI, 7.4–not achieved) in the MLND group (P ¼ .25;
Figure 2, Table 2). Similar results were observed when the
analysis was performed on all 1111 randomized subjects;
the median survival in the MLNS group was 8.1 years
(95% CI, 7.0–9.0) versus 8.4 years (95% CI, 7.3–not
achieved) in the MLND group (P ¼ .34). There were 285
recurrences reported, including 54 local, 74 regional, and
225 distant recurrences in the eligible subjects. Of these,
138 (24 local, 43 regional, and 111 distant) recurrences
were in the MLNS arm and 148 (30 local, 31 regional,
and 114 distant) recurrences were in the MLND arm. The
5-year disease-free survival was 69% (95% CI, 64–74) in
the MLNS arm and 68% (95% CI, 64–73) in the MLND
arm (P ¼ .92; Table 2). Similar results were obtained onThe Journal of Thoracic and Caall randomized subjects; 5-year disease-free survival was
68% (95% CI, 64–73) in the MLNS group and 67%
(95% CI, 62–71) in the MLND group (P ¼ .89). An addi-
tional analysis was performed separately for T1 (P ¼ .83)
and T2 (P ¼ .63) tumors and no differences were observed
in disease-free survival between treatment arms (Table 3).
There was no difference among local (P ¼ .52), regional
(P ¼ .10), or distant (P ¼ .76) recurrence between the 2
treatment arms. Similar results were observed for all ran-
domized subjects (P ¼ .54, P ¼ .24, and P ¼ .77 for local,
regional, and distant recurrence, respectively).
DISCUSSION
This prospective randomized controlled clinical trial
found no difference in long-term survival between MLND
and MLNS during pulmonary resection for patients with
T1 or T2, N0 or nonhilar N1 NSCLC. We also did notrdiovascular Surgery c Volume 141, Number 3 665
TABLE 3. Disease-free survival in T1/T2 eligible patients
Disease-free survival in T1/T2 eligible patients
Time
T1 MLNS estimate (95%
CI) (%)
T2 MLNS estimate (95%
CI) (%)
T1 MNLD estimate (95%
CI) (%)
T2 MNLD estimate (95%
CI) (%)
2 y 87.2 (82.5–92.1) 75.1 (69.5–81.2) 91.0 (87.1–95.1) 71.7 (66.0–77.9)
4 y 79.4 (73.7–85.6) 64.7 (58.3–71.7) 82.1 (76.6–87.9) 62.9 (56.7–69.8)
6 y 75.0 (68.5–82.1) 58.1 (51.2–65.8) 73.7 (67.1–81.0) 59.0 (52.6–66.3)
8 y 69.7 (61.5–79.0) 54.8 (47.0–63.7) 66.3 (58.0–75.8) 53.0 (45.5–61.7)
MLNS, Mediastinal lymph node sampling; MLND, mediastinal lymph node dissection; CI, confidence interval.
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recurrence between MLND and MLNS groups. Previous
reports from this trial showed no increase in morbidity or
mortality with the addition of MLND.6
After Evarts A. Graham’s first successful pneumonec-
tomy, surgical resection for lung cancer became popular
in the United States. Pneumonectomy remained the main-
stay of therapy until it was challenged by Johnson and col-
leagues.8 Subsequently, in a 1962 report by Shimkin and
colleagues,9 lobectomy was shown to be acceptable ther-
apy. Although the extent of resection was reduced, removal
of all mediastinal lymph tissue was still considered neces-
sary, extrapolating from other solid tumors, such as breast
or gastric cancer, for which removal of all the draining
lymph nodes was considered the standard of care. In a report
on complete mediastinal lymphadenectomy in 1951, Cahan
and colleagues10 (from the Memorial Sloan Kettering Can-
cer Center) found ‘‘that some patients experienced long-
term survival when the positive regional lymph nodes also
were removed.’’ In a subsequent review, Martini11 com-
mented that complete MLND led to ‘‘more favorable
long-term survival.’’ Thus, complete MLND has been con-
sidered the standard of care for lung cancer resection at
most academic centers.
This ‘‘standard’’ has not been followed by the majority of
surgeons. In a review of surgical care in the United States in
2001, Little and colleagues2 found that only 57.8% of pa-
tients who had surgery as their initial treatment of lung can-
cer had any mediastinal lymph nodes sampled or removed.
In community hospitals, the rate of any surgical lymph node
assessment was even lower at only 48.1%.
MLND improves staging accuracy by increasing lymph
node harvest and improving identification of occult N2 dis-
ease.12-14 However, whether survival is improved byMLND
is controversial. In a subgroup analysis of patients with stage
II or IIIA NSCLC entered into Intergroup trial 0115 of
adjuvant chemoradiotherapy versus radiotherapy after
resection, Keller and colleagues15 reported improved long-
term survival in patients with right upper lobe tumors who
had MLND with a median survival of 57.5 months versus
MLNS with a median survival of 29.2 months. The choice
of MLND versusMLNSwas not randomized and was based
on surgeon preference. In contrast with the Z0030 study,666 The Journal of Thoracic and Cardiovascular SurgKeller and colleagues’ analysis included only patients who
had positive N1 or N2 nodes. There was no difference in
the recurrence rates between the 2 cohorts.
A randomized trial comparing MLND and MLNS in 169
patients with stage I, II, or IIIA NSCLC reported by Izbicki
and colleagues16 found no significant difference in survival
after a median follow-up of 47.5 months. In the MLND
group, lymph nodes were removed from stations 12, 11,
10, 7, 4, and 5 in all patients, whereas in the sampling group
mediastinal nodes were removed only if they appeared sus-
picious. At a median follow-up of 47.5 months, therewas no
difference in overall or disease-free survival except in pa-
tients with N1 or single-station N2 nodes in whom both
overall and disease-free survival was improved. Although
their sampling methodology was a bit different than ours,
they also found only a small number of patients (5.5%)
had unsuspected mediastinal lymph node involvement after
MLND.
By using a protocol similar to that in Izbicki and
colleagues’ study16 in patients with clinical stage I small
(<2 cm) T1 NSCLC (87% nonsquamous cancers), Sugi
and colleagues14 found no difference in survival between
the MLND and MLNS groups (5-year survival: 81% and
84%, respectively). Unsuspected N2 disease was identified
in 12% and 14% ofMLND andMLNS groups, respectively.
However, a larger randomized trial of 532 patients with
clinical stage I, II, or IIIA NSCLC reported by Wu and col-
leagues,3 comparing MLND with MLNS, reported signifi-
cantly improved survival with MLND. The median
survival was 43 months in the MLND group and only 32
months in the MLNS group (P ¼ .0001). By multivariate
analysis, the number of lymph node metastases, type of
nodal dissection (MLND vs MLNS), tumor size, and path-
ologic stage were all significant prognostic factors.
In contrast with those in the ACOSOG Z0030 trial, the
patients in the trial reported by Wu and colleagues3 were
only staged clinically before randomization. As a result,
48% of the patients in the MLND had pathologic stage
IIIA disease versus 28% in the MLNS arm. Furthermore,
in the MLNS arm, mediastinal nodes were sampled only
if suspicious (>1 cm) or hard. Unlike in the ACOSOG
Z0030 trial, systematic sampling of the mediastinal nodes
was not performed.ery c March 2011
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vantage for stages I, II, and IIIA, and a fixed-effects model
reported by the same group reported MLND reduced the
risk of death for early-stage disease.17,18
The ACOSOG Z0030 protocol required systematic sam-
pling of mediastinal nodes by mediastinoscopy, thoracot-
omy, or VATS. In addition, any suspicious nodes were
also sampled. Only after all required node stations were
proven to be negative for metastatic disease was the patient
eligible for randomization to no further lymph node re-
moval (MLNS) or to formal complete lymph node dissec-
tion (MLND). This process allowed us to eliminate many
patients who may have had ‘‘occult’’ positive mediastinal
lymph nodes and explains the low (4%) incidence of unsus-
pected N2 disease found in patents who underwent com-
plete mediastinal lymphadenectomy. In this regard, the
Z0030 trial differs from previous randomized trials in that
all patients truly had early-stage disease.
Lymph node sampling by mediastinoscopy, VATS, or
thoracotomy was equally efficacious in accomplishing
systematic lymph node sampling. Endobronchial
ultrasound-transbronchial needle aspiration and endoscopic
ultrasound-fine-needle aspiration were not evaluated in this
trial.
Clinical staging with computed tomography (CT) and
positron emission tomography is not equivalent to surgical
staging; thus, in the absence of surgical staging of the me-
diastinal lymph nodes as was performed in the Z0030 trial,
MLND is essential for both accurate staging and improved
survival, as suggested by Wu and colleagues.3 In patients
who are surgically staged as in our trial, MLND identifies
truly occult N2 disease and thereby provides such patients
with the opportunity to receive adjuvant chemotherapy,
which has now been shown to improve survival. At the
time this study was performed, adjuvant chemotherapy
was not the standard of care, which may have contributed
to the lack of survival benefit in the MLND arm.
Determination of the amount of lymph node tissue re-
moved in both arms of the trial was based on the number
or fragments of nodes rather than the weight, and this has
some inherent inaccuracies. This is a limitation of the study
and may have contributed to the lack of difference between
the 2 arms of the trial.
This study was conducted by many surgeons, all
American Board of Thoracic Surgery (or equivalent) certi-
fied and in many institutions (both community and aca-
demic); thus, the results are generalizable and not limited
to a few specialized surgeons or centers. The breadth of
surgical participation also introduced a potential problem
of standardization. However, because each operative and
pathology note was reviewed by one of the principle inves-
tigators (M.S.A. or G.E.D.), the variation was minimized,
and patients with inadequate MLND or overly aggressive
sampling were deemed ineligible.The Journal of Thoracic and CaCONCLUSIONS
MLND does not improve long-term survival in patients
with early-stage (T1 or T2, N0 or nonhilar N1) NSCLC
who have pathologically negative mediastinal and hilar no-
des after rigorous systematic preresection lymph node sam-
pling. In such patients, MLND also does not affect the rate
of local or regional recurrence. Our results do not apply to
patients with T3 or T4 tumors or those with known hilar
or N2 disease because they were not included in our study.
Staging by positron emission tomography-CTor CTalone is
not equivalent to the invasive staging performed in this
study, and surgeons cannot use this study to justify exclud-
ing invasive mediastinal staging from their evaluation of
patients with early-stage NSCLC.
MLND provides patients with the most accurate staging
and the opportunity for adjuvant therapy if occult metastatic
disease is present. Because current preoperative staging
cannot definitively identify patients with mediastinal lymph
node involvement, and because patients with known hilar or
mediastinal disease (N2) or with T3 or T4 tumors may ben-
efit from MLND because the pretest probability of N2 dis-
ease is higher, we still recommend that all patients with
resectable NSCLC undergo MLND because the procedure
does not increase mortality or morbidity.
The authors thank the late Dr Robert J. Ginsberg for valuable
leadership in designing this trial.
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Dr Joseph Shrager (Stanford, Calif). I have no conflicts. I con-
gratulate Dr Darling and coauthors for a carefully conducted study
on a subject that has daily practical relevance. We heard from this
data set in 2005 that lymph node dissection causes no increasedmor-
bidity or mortality versus sampling, and today’s presentation gives
us the long-awaited survival data. The results, as you heard, show
that there is no difference in either overall or disease-free survival
whether one does a complete dissection versus an aggressive sam-
pling in the early stages thatwere studied. But despite these findings,
you recommend that a complete dissection is the procedure of
choice, because, and I quote loosely, ‘‘it improves the accuracy of
staging and thus the selection of patients for adjuvant therapy.’’
I would agree with your conclusion that complete dissection
remains preferable, but for completely different reasons than those
you describe. Only 4% of additional patients were found to have
positive nodes at dissection that were missed at sampling, and
presumably most of these patients then received adjuvant chemo-
therapy, yet there was still no survival advantage to the dissection.ery c March 2011
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SSo I don’t understand why ‘‘better staging’’ is a good reason to do
a complete dissection, and I don’t think that surgeons will buy that
reasoning, honestly.
My reasoning for continuing to do complete dissections would
be that the sampling stipulated in the protocol is not at all a real-
world sampling, and few surgeons would actually be doing that
type of extensive sampling. With a less extensive, more real-world
sampling, you would have found more than 4% additional nodes at
complete dissection, and so you would possibly also have found
a significantly increased survival. So I think it is dangerous for ev-
eryone to leave the meeting thinking that sampling is okay. As you
emphasized, sampling is only okay if you have done this particular
systematic, extensive sampling with frozen sections as stipulated
in the study, and that is a sampling that pretty much approached
being a total lymphadenectomy. If your sampling is going to be
that extensive, it is probably more efficient to just do a lymphade-
nectomy from the start. I have 3 specific questions.
First, the article describes a power analysis that arrived at a tar-
get accrual of 1037, which you nearly achieved, but I would guess
that that power analysis was based on a likelihood of identifying
more than only 4% additional nodes at the time of the lymphade-
nectomy. So are you concerned that you have sort of a type II error,
that is, a false-negative result?
Dr Darling. First, my comment on your comment, and that is
we know from the previous pattern of care study that you are cor-
rect. In fact, less than half the patients who have surgery for
NSCLC in North America actually have any kind of lymph node
sampling performed at mediastinoscopy or before resection. So
these results don’t reflect the real world but may inform real-world
practice, and I would echo your comments that the patients were
rigorously staged and our results don’t apply to patients who don’t
have that kind of sampling. This is supported by the literature. The
survival benefit for lymph node dissection shown in studies was in
a group of patients who did not have any kind of preresection sam-
pling or staging, and therefore their finding of so-called occult N2
disease was much higher.
In terms of your question about the power, the overall sample
size was based on the primary aim of comparing overall survival
betweenMLND andMLNS. Because of the limited number of sub-
jects enrolled with higher stage disease (ie, pN1 and pN2/pIIIA),
the power for the study was amended. This amendment was ap-
proved by the National Cancer Institute. The amended power cal-
culation presented in the article assumes the following proportions
for stage groups pT1N0 (41%), pT2N0 (41%), pN1 (13%), and
pN2/IIIA (4%) in theMLNS arm. The power calculation was based
on a 1-sided, alpha ¼ 0.05 log rank test for 90% power, which re-
sulted in needing to enroll 1037 subjects. We enrolled 1111 sub-
jects, of whom 1023 were deemed eligible. As described in the
article, both intent-to-treat analyses on all randomized subjects
and analyses limited to the eligible subjects were performed. Var-
ious power scenarios were considered for the secondary aim of
identifying occult metastases. For example, if 5% pN2 nodes
were discovered in theMLNS versus 10% in the MLND dissection
arm, there would be more than 90% power. On the basis of the ob-
served differences, we think the study was adequately powered.
Dr Shrager. You showed us the results in the T1 and T2
subgroups. I wonder about the N0 and N1 subgroups. Because
there is certainly going to be more occult N2 disease in thoseThe Journal of Thoracic and Cawith clinical N1 than in those with clinical N0, most of us would
be pretty concerned about leaving out a complete lymphadenec-
tomy in somebody who has clinical N1.
DrDarling. The study protocol mandated that only patients with
nonhilar N1 were eligible and the hilar nodes had to be sampled,
proven to be negative by frozen-section for the patient to be eligible.
The actual number of patients withN1 is relatively small. So anyN1
nodes that were present were actually within the lobectomy speci-
men. This is similar to the real world: The surgeon would not
know the status of the intralobar nodes, only the hilar nodes. So,
in the study population, the highest resected nodes were negative.
Dr Shrager. I wonder if you think this study has any relevance
to the role of VATS lobectomy? As you know, many continue to
find that doing a true complete mediastinal lymphadenectomy is
difficult to do thoracoscopically. However, if complete dissection
is of little benefit over a good sampling, is the last barrier to a wider
acceptance of VATS lobectomy for earlier stage disease gone?
Dr Darling. If we are going to do lung cancer surgery by VATS,
we need to do the same operation that we do when we do it open,
and that includes a lymph node dissection or a rigorous sampling,
and I don’t think it is appropriate for us to just simply go in and
take out the lobe and not do a proper sampling of the lymph nodes.
Only 7% of the patients in this study were resected by VATS, and
that was primarily done by one surgeon. Dr Allen and I reviewed
all the path and operative notes from all the patients in the trial, and
particularly we reviewed those VATS cases because of our bias that
maybe they wouldn’t have had an adequate dissection or sampling.
In that particular surgeon’s hands, an adequate dissection was done
and the lymph node counts were comparable to those taken with
open surgery. So I think it is possible to do a good lymph node dis-
section or sampling with VATS technique, and it behooves us as
thoracic surgeons who treat lung cancer to do the same job with
VATS as we do with open.
Dr Thomas D’Amico (Durham, NC). Could you just clarify
how you did the audit to make sure that a sampling or a dissection
was done?
Dr Darling. As I mentioned, we reviewed all the operative
notes and looked at the numbers of lymph nodes that were actually
removed, and we actually disqualified some patients because they
had excessive sampling or had not had an adequate dissection.
Dr Allen and I both reviewed those results. We eliminated some
of the patients because they didn’t follow the protocol.
Dr D’Amico. What percentage of patients were upstaged so
that treatment was changed? Were any of the 4% of N2 also N1
so that they would have received chemotherapy anyway?
Dr Darling. Of the 21 patients, 11 had N1 disease. This trial
was completed in 2004. So at that time, adjuvant chemotherapy
was not recommended for N1 disease. In reference to Dr Shrager’s
previous comment, these patients did not necessarily receive adju-
vant therapy at that time, but nowadays they would, and this may
have improved survival.
Dr Marcin Zielinski (Zakopane, Poland). I have 2 questions.
First, what was the mean number of nodes removed during lym-
phadenectomy in the lymphadenectomy group?
Dr Darling. The median number of N2 nodes taken was 11 on
the right and 12 on the left, but if all nodal stations are included, the
median number of nodes taken was 18. Ninety-nine percent of our
patients had 6 or more nodes taken from 3 mediastinal lymph noderdiovascular Surgery c Volume 141, Number 3 669
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Commentary Murthystations and 90% had 10 or more nodes removed from 3 mediasti-
nal lymph node stations.
Dr Zielinski. My second question is, do you know how many
patients were positive on the initial sampling with frozen-section?
Dr Darling. We don’t have that data because they were not
eligible to be randomized.
Dr Paul De Leyn (Leuven, Belgium). That was a nice presenta-
tion. When you read the article in 2005, which describes morbidity
and mortality, you indeed think that the sampling is already exten-
sive, and this is important. Can you describe from a technical point
of viewwhen you sample, let’s say, station 7, is this just picking out
a few nodes or is this removing this whole station? What is the dif-
ference between sampling and dissection in your study?COMMEN
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670 The Journal of Thoracic and Cardiovascular SurgDrDarling.The sampling protocol specified that you were sim-
ply directed to sample one node from each station. If there were
any suspicious-looking nodes, obviously they were also required
to be sampled as opposed to doing a formal clean-out of the
area. So the protocol did specify to sample 1 node. Occasionally
the surgeons would take more than 1 node, but, as I mentioned,
if they took a whole lot of nodes (eg, 5–7 nodes from station 7),
we disqualified those as being a dissection rather than a sampling.
For the lymph node dissection, the protocol specified removing all
lymph node-bearing tissues between anatomic boundaries. For ex-
ample, for stations 2R and 4R all tissue between the superior vena
cava, trachea, right innominate artery, and the right bronchus was
removed, not just the visible lymph nodes.TARYLess is more. (more or less.)Sudish C. Murthy, MD, PhDIn this month’s issue, Dr Darling and colleagues present the
results of a long-awaited multicenter, prospective, random-
ized trial comparing efficacy of mediastinal lymph node
sampling (MLNS) and mediastinal lymph node dissection
(MLND) for localized non–small cell lung cancer (NSCLC).
This study was one of the many ‘‘brain-children’’ of the late
Dr Robert J. Ginsberg, and its organization, attention to de-
tail, and insight speak to the lasting legacy of this pioneer. In
addition, the group of distinguished authors who carried this
trial to its conclusion has overcome enormous obstacles to
complete this ambitious enterprise, dutifully and meticu-
lously organizing data collected from over 100 surgeons at
63 member institutions while maintaining some element
of quality control throughout the process—truly a formida-
ble task whose complexity should be appreciated.
The importance of this trial cannot be underestimated in-
asmuch as the role of lymphadenectomy for NSCLC, until
now, has served as a point of confusion for most thoracicsurgical oncologists. Although widely heralded as an im-
portant adjunct for management of the disease, there has
been little evidence to support this grandiose contention
in clinical practice. In fact, a shockingly high number of
lung cancer operations are performed without a single me-
diastinal lymph node even being sampled.1 Yet, despite this,
sophisticated and detailed guidelines of howMLND should
be integrated into NSCLC management have continued to
emerge.2 At last, there is a well-done, randomized trial to
support a position on the subject.
The findings of this trial are provocative, as surprisingly,
equivalence was found between MLNS and MLND for pa-
tients with early NSCLC (N0 or nonhilar N1 cancers). This,
in part, corroborates results from a similar, albeit much
smaller and less well-controlled, trial from a decade ago.3
But the results appear to fly against the popular notion
that MLND is a superior surgical technique with important
survival benefits for patients with early-stage NSCLC.4-7
None of these lesser studies was randomized or as well
conceived, however. Importantly, after careful review of
each study, including my own, unfortunately, the authors
of the latter group of manuscripts need not ready their
retraction statements just yet, inasmuch as there may still
be room for peaceful coexistence between studies,
because slightly different questions were addressed by each.
There is a reason why such randomized studies are com-
pleted so infrequently and why this trial casts such a heroic
specter. Clearly, it is difficult to have equipoise for such
a trial if one believes strongly (either way) about MLND,ery c March 2011
